An observational study, Garmin PACT, investigating physical activity tracking in Type 1 Diabetes using a Garmin Vivosmart device, was terminated on 2025-10-20 after enrolling 45 participants.
Background
Type 1 Diabetes (T1D) is an autoimmune condition where the body does not produce insulin, a hormone essential for regulating blood sugar. Managing T1D involves careful monitoring of glucose levels, insulin administration, and lifestyle adjustments, including diet and physical activity. Regular physical activity is crucial for individuals with T1D as it can improve insulin sensitivity, help manage weight, and contribute to overall cardiovascular health. However, balancing physical activity with blood sugar management can be challenging, requiring careful planning to prevent hypoglycemia or hyperglycemia. Wearable technology, such as fitness trackers, offers a potential tool for monitoring and encouraging physical activity, especially in younger populations who may benefit from engaging and accessible health management tools.
Trial design
The Garmin PACT study (NCT05992350) was an observational study that enrolled 45 children and youth aged 8-21 with Type 1 Diabetes, along with their parents. The trial's overall status was TERMINATED. The study aimed to test the Garmin Vivosmart (version 4 or higher) in this population. Participants were instructed to wear the Garmin Vivosmart for one year and complete surveys at the beginning, middle, and end of their participation, covering aspects of T1D, T1D management, and physical activity. Parents of the children also completed similar surveys. The main questions the study sought to answer were whether the Garmin Vivosmart could increase physical activity and improve T1D status. No specific interventions or primary outcome measures were listed for this observational study.
What this means
The termination of the Garmin PACT study means that the initial questions regarding the Garmin Vivosmart's impact on physical activity and T1D status in children and youth with Type 1 Diabetes were not fully addressed within this specific trial. While 45 participants were enrolled, the study's termination indicates that it did not proceed to completion as originally planned. The reasons for termination are not provided in the available data. Therefore, the potential benefits or limitations of using the Garmin Vivosmart for physical activity tracking in this population remain to be definitively established by this particular study.
Source
The information regarding this study's termination and design was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05992350, titled "Garmin PACT (Physical Activity Tracking in Type 1 Diabetes Using Garmin Vivosmart)", were posted on 2025-10-20 on clinicaltrials.gov.